Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin Data Showing Superiority Over Lipitor Added To Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck/Schering-Plough’s labeling update for Vytorin includes results of the VYVA study.

You may also be interested in...



Vytorin Label Adds Superiority Data Over Crestor

FDA approved the inclusion of new data on the cholesterol-lowering efficacy of the ezetimibe/simvastatin fixed-dose combination.

Vytorin Label Adds Superiority Data Over Crestor

FDA approved the inclusion of new data on the cholesterol-lowering efficacy of the ezetimibe/simvastatin fixed-dose combination.

Vytorin Outpaces Crestor In Comparison Study

Schering-Plough/Merck’s ezetimibe/simvastatin combination shows better LDL cholesterol reduction than Crestor.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel